

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: September 15–17, 2010.

Time: September 15, 2010, 1:30 p.m. to 5:30 p.m.

Agenda: The Office of Biotechnology Activities (OBA) and NIH Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols as well as related data management activities. Please check the meeting agenda at http://oba.od.nih.gov/rdna_rac/rac_meetings.html for more information.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Executive Meeting Center, Rockville, MD 20852.

Time: September 16, 2010, 8 a.m. to 5:30 p.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols, have a discussion of ethical considerations in review of pediatric protocols, and discuss related data management activities. Please check the meeting agenda at http://oba.od.nih.gov/rdna_rac/rac_meetings.html for more information.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Executive Meeting Center, Rockville, MD 20852.

Time: September 17, 2010, 8 a.m. to 1 p.m.

Agenda: The Recombinant DNA Advisory Committee will review and discuss selected human gene transfer protocols, have a discussion of ethical considerations in review of pediatric protocols, and discuss related data management activities. Please check the meeting agenda at http://oba.od.nih.gov/rdna_rac/rac_meetings.html for more information.

Place: Hilton Washington/Rockville, 1750 Rockville Pike, Executive Meeting Center, Rockville, MD 20852.

Contact Person: Chezelle George, Office of Biotechnology Activities, Office of Science Policy/OD, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892. 301–496–9838. georgec@od.nih.gov.

Information is also available on the Institute's/Center's home page: <http://oba.od.nih.gov/rdna/rdna.html>, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: August 17, 2010.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–20861 Filed 8–20–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of a Meeting of a Working Group of the NIH Advisory Committee to the Director

The purpose of this notice is to inform the public about a meeting of the NIH Blue Ribbon Panel to Advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University Medical Campus.

The meeting will be held Wednesday, September 22, 2010 at the Hyatt Regency Bethesda, 7400 Wisconsin Avenue, Bethesda, MD 20814 from approximately 8:30 a.m. to 3:30 p.m.

This meeting is the third in a series of public meetings between the Blue Ribbon Panel and the National Research Council Committee on Technical Input (NRC Committee) to review and discuss

the ongoing supplementary risk assessment study being conducted for the Boston University NEIDL.

The meeting will be open to the public, with attendance limited to space available. There will be a live webcast of the meeting which can be accessed at <http://nihblueribbonpanel-bumc-neidl.od.nih.gov/>. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person listed below in advance of the meeting.

Oral public comment will begin at approximately 3 p.m. Written comments may be provided, as well, by sending them to the address below. Written comments must be postmarked by October 1, 2010 and should include the name, address, telephone number and, when applicable, the business or professional affiliation of the commenter.

A draft agenda and slides for the meeting may be obtained by connecting to <http://nihblueribbonpanel-bumc-neidl.od.nih.gov/>. For additional information concerning this meeting, contact Ms. Kelly Fennington, Senior Health Policy Analyst, Office of Biotechnology Activities, Office of Science Policy, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892–7985; telephone 301–496–9838; e-mail fennington@nih.gov.

Dated: August 16, 2010.

Amy P. Patterson,

Acting Director, Office of Science Policy, National Institutes of Health.

[FR Doc. 2010–20860 Filed 8–20–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract